GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)-- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx Gastrointestinal Panel 2 Mini B for clinical use, further strengthening its syndromic testing portfolio in the United States.

This marks QIAGEN’s second FDA clearance of a QIAstat-Dx panel in 2025, and builds on the authorization of five panels for use on the QIAstat-Dx system within the last 10 months.

QIAGEN has now received regulatory clearances for three mini panels for detection of respiratory and gastrointestinal conditions, with these panels designed for outpatient use to aid fast and informed treatment decisions.

ROCKVILLE, Md. and SUZHOU, China, March 05, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for hematological malignancies, today announced that its drug, olverembatinib, has been granted a Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA), for combination with low-intensity chemotherapy for the first-line treatment of newly-diagnosed patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).

By Sara Gilgore – Staff Reporter, Washington Business Journal -Mar 5, 2025 - A New York health care technology company that recently adopted a new name has also found a new home — in Greater Washington.

Claritev Corp. (NYSE: CTEV), a 45-year-old firm previously known as MultiPlan Corp. (NYSE: MPLN), has moved its corporate headquarters to McLean, according to filings with the Securities and Exchange Commission.

The building at 7900 Tysons One Place, known as Tysons Tower, also counts Intelsat Corp. and Deloitte LLP as tenants.

Claritev’s move to McLean represents somewhat of a fresh start for the business, which last year lost $1.6 billion and was hit with several lawsuits from the American Medical Association and several health systems alleging it colluded with insurers to underpay doctors.

Life sciences company developing a cost-effective production process for cancer immunotherapies

COLUMBIA, Md., (March 5, 2025) — TEDCO, Maryland’s economic engine for technology companies, announced a recent $500,000 Life Sciences Investment Fund (LSIF) investment in Irazú Oncology. The LSIF is nestled under the umbrella of TEDCO’s Seed Funds and is dedicated to supporting qualifying startups with an FDA pathway.

"At Irazú Oncology, we are committed to developing cancer therapies that are both more versatile and accessible to patients worldwide," said Jeff Strovel, CEO of Irazú Oncology. "TEDCO's support has been instrumental in advancing our innovative platform. Their MII program and strategic investments have enabled us to accelerate our research and development efforts, bringing us closer to our mission of delivering more effective cancer treatment options. I would encourage researchers and emerging biotech companies to explore the remarkable opportunities that TEDCO offers to help translate promising science into life-changing therapies."

USP publishes Vulnerable Medicines List to inform efforts to reduce risk and increase supply chain reliability for patients 

Rockville, MD – The U.S. Pharmacopeia (USP) today published the “2024-2025 Vulnerable Medicines List for the United States: A data-based approach to identify risks and enable interventions to increase reliability of supply”. This list complements other resources, such as FDA’s essential medicines list. 

Using the USP Medicine Supply Map and other resources, USP identified 100 vulnerable medicines – 49 used to manage chronic conditions and 51 for acute care – to encourage dialogue and action to bolster medicines supply chain resilience. A public list of medicines vulnerable to shortage can help stakeholders work more effectively to make the medicine supply chain more reliable for patients. 

ROCKVILLE, Md., March 4, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the closing of its previously announced strategic partnership with Nippon Shinyaku.

Under the terms of the agreement, REGENXBIO and Nippon Shinyaku will develop and commercialize RGX-121 (clemidsogene lanparvovec) for Mucopolysaccharidosis II (MPS II), also known as Hunter syndrome and RGX-111 for Mucopolysaccharidosis I (MPS I), also known as Hurler syndrome in the United States and Asia.

POTOMAC, MD / ACCESS Newswire / March 4, 2025 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced an advancement in its Artificial Intelligence ("AI") platform with the development of a new AI-driven model designed to improve the diagnosis of Alzheimer's disease (AD) and other causes of dementia. With Alzheimer's accounting for approximately 60-80% of all dementia cases, alongside other conditions such as vascular disease, Lewy body disease, and frontotemporal degeneration, accurate diagnosis is critical to ensuring the right treatment strategy.

Dementia affects over 55 million people worldwide, causing progressive cognitive decline, memory loss, and behavioral changes. Despite its widespread impact, current diagnostic methods often rely on invasive procedures, expensive imaging, and subjective clinical assessments, leading to high rates of misdiagnosis and delayed treatment.

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, announced today an indication expansion for its industry leading genetic testing to now include cerebral palsy (CP). In conjunction with Cerebral Palsy Awareness Month, the company is expanding its strategy of focusing on pediatric rare disease patients to now include offering testing for pediatric patients with CP. This strategic indication expansion underscores the importance of improving access to exome and genome testing for patients with CP to shorten the diagnostic odyssey and accelerate the path to treatment.

By Kevin Davies, PhD - March 3, 2025 - After an illustrious career including 12 years as director of the National Institutes of Health (NIH) and leading the international Human Genome Project (HGP) consortium, Francis Collins, MD, PhD, announced his sudden resignation from the NIH over the weekend.

He joined the NIH in 1993, a guitar-playing physician-scientist (and born-again Christian) who could not resist the challenge of helming the sequencing of the human genome. “How could I walk away from the chance to lead such an historic enterprise?” he wrote.

Collins served three presidents during his 12 years as NIH director, including the onset of the COVID-19 pandemic. He also served as chief White House science advisor to President Biden, accepting the position following the sudden resignation of his HGP ally, Eric Lander, PhD. Throughout his tenure, Collins maintained his research lab at the NHGRI, publishing a paper in GEN’s sister peer-reviewed journal, The CRISPR Journal, led by Lori Bonnycastle, PhD, 12 months ago on the generation of induced pluripotent stem cell lines using prime editing.

Since I have been raising and deploying a venture fund focused on addressing health of women lately, I have had numerous occasions to be in rooms where the discussion ended up at “it’s really hard to raise venture capital for women’s health companies.”  The whole discussion of venture funding for women’s health (and by women’s health, I do NOT mean things that are limited only to conditions faced ONLY by women) is getting a lot of play lately as many organizations have, thankfully, risen to the occasion of developing funds to drive this market forward.  Granted, most of these funds remain on the small side and there are many entrepreneurs competing for these fresh new greenbacks, but hey, progress is progress.

By Annabel Baldy - In November’s What’s the Buzz?! LinkedIn Live session, Chris Frew, CEO of BioBuzz and Tammi Thomas, Chief Development & Marketing Officer, TEDCO explored TEDCO’s profound influence on Maryland’s entrepreneurial landscape. For over 26 years, TEDCO has played a pivotal role in fostering the growth of technology and life science startups, driving innovation, creating jobs, and strengthening the regional economy.

The TEDCO Entrepreneur Expo: Connecting Entrepreneurs to Resources
A key highlight of the discussion was the TEDCO Entrepreneur Expo, held in December in Baltimore. As a premier networking event, the Expo provides entrepreneurs with access to critical resources, direct connections with industry leaders, and insights into funding opportunities. Events like these are essential for cultivating an environment where startups can thrive. TEDCO’s funding programs not only inject capital into the economy but also fuel job creation and technological advancements.

By Alex Philippidis - February 26, 2025 - The FDA has granted Priority Review to Precigen’s Biologics License Application (BLA) for its lead candidate PRGN-2012, the company said—a step forward for a gene therapy that, if approved, would be the first treatment indicated for adults with the rare disease of recurrent respiratory papillomatosis (RRP).

The FDA also set an August 27 target date for deciding on Precigen’s BLA under the Prescription Drug User Fee Act (PDUFA). PRGN-2012—which Precigen has begun to call by its generic name of zopapogene imadenovec—is a gene therapy designed to elicit immune responses directed against cells infected with human papillomavirus (HPV) 6 or HPV 11.

Protenus, a leading healthcare compliance analytics platform that serves over 200 healthcare organizations, was acquired in January 2025 by Bluesight, a prominent provider of inventory management, procurement, and compliance solutions for health systems and hospital pharmacies. This acquisition marks a significant milestone in Protenus’ journey, which began nearly 12 years ago at Johns Hopkins University.

The story of Protenus began with the initiation of DreamIt Health Baltimore (BHI was also a DreamIt Partner), a former accelerator the university helped sponsor, which was organized by its parent company, DreamIt Ventures. The program received about 100 applications, and 10 teams were selected for the first cohort. Among them were medical students Nick Culbertson and Robert Lord. Initially, they set out to innovate in the digital health space without a specific product in mind however, their journey changed after they connected with Peter Greene, the Chief Medical Information Officer of Johns Hopkins Medicine.

BALTIMORE--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced the initiation of a fully funded Phase 2b clinical trial evaluating oral TNF-alpha (TNF-α) inhibitor drug candidate isomyosamine as a treatment for chronic inflammation associated with muscle loss (frailty or sarcopenia) in patients who have undergone hip or femur fracture repair surgery.

COLUMBIA, Md., (February 25, 2025) — TEDCO, Maryland’s economic engine for technology companies, announced a recent $250,000 Venture Funds investment in Pathotrak. TEDCO’s evergreen Venture Funds are dedicated to funding and growing the next generation of early-stage technology and life sciences businesses in Maryland. Through this fund, companies are offered an experienced team that is focused on supporting the entrepreneurial journey.

“Ensuring food safety is a growing challenge, and current testing methods are often slow and costly for producers,” said Javier Atencia, CEO of Pathotrak. “With TEDCO’s continued support, we are advancing our technology in an effort to shorten the time required for pathogen detection, empowering manufacturers with what we hope are faster, more reliable solutions.”

By Benjamin Mueller -The Trump administration stormed into office, loudly firing workers and closing diversity programs. But behind the scenes, it has also brought biomedical research to the brink of crisis by holding up much of the $47 billion the United States spends on the field every year.

The world’s leading medical labs can be found in the United States, and they rely on grants from the National Institutes of Health. The agency has stopped vetting future studies on cancer, Alzheimer’s, heart disease and other ailments. Trump aides have said they just need time to review spending their predecessors had promised, but it’s unclear what they’re looking for at the N.I.H. or when scholars can expect to start receiving money again.

In today’s newsletter, I’ll walk you through what happened — and why it matters.

On April 1, 2025, Georgetown University’s Office of Technology Commercialization, in partnership with the Georgetown Entrepreneurship Initiative, will host the first-ever Georgetown Research and Innovation Showcase. This half-day event will bring together researchers, entrepreneurs, investors, and industry leaders to highlight groundbreaking discoveries and explore commercialization opportunities.

Attendees can expect engaging research presentations, an industry panel discussion, and a fast-paced Venture Fair, where selected faculty, student, and alumni-led startups will pitch their disruptive technologies to an audience of venture capitalists, angel investors, and corporate innovation teams.

The event will culminate in a networking reception, offering a unique opportunity for collaboration and funding discussions between the Georgetown community and key industry players. Whether you’re an innovator, investor, or looking to connect with cutting-edge ventures, this is an event you won’t want to miss.

📅 Date: April 1, 2025
🕜 Time: 1:30 PM – 6:30 PM ET
📍 Location: Georgetown University

Don’t miss your chance to be part of this exciting showcase of innovation and entrepreneurship!

https://otc.georgetown.edu/newsevents/research-and-innovation-showcase-2025/

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today announced it is in the final stages for the launch of its 212-patient Confirmatory Registration Study for Multikine* (Leukocyte Interleukin, Injection) in newly diagnosed locally advanced head and neck cancer patients. This final Registration Study is specifically designed to confirm the statistically significant efficacy and safety results from CEL-SCI’s previously completed randomized controlled Phase 3 trial.

GERMANTOWN, Md.--(BUSINESS WIRE)--Amarex today announced its work on behalf of Britecyte has resulted in a “safe to proceed” status by the United States Food and Drug Administration (FDA) for its Adipose Tissue Allograft (BRC-OA).

BALTIMORE, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Elixirgen Therapeutics, Inc., a clinical-stage biotechnology company focused on treating rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to EXG-34217, a gene therapy for treatment of Telomere Biology Disorders (TBDs). EXG-34217 is currently being studied in an ongoing Phase 1/2 trial (NCT04211714) for the treatment of patients with TBDs with bone marrow failure. Enrollment is currently open for participants aged 12 and older, regardless of gender or ethnicity.

The FDA recently granted EXG-34217 Rare Pediatric Disease Designation (RPDD) and Regenerative Medicine Advanced Therapy (RMAT) Designation.

ANNAPOLIS, Md., Feb. 19, 2025 /PRNewswire/ -- Alphyn, a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics^®, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for Zabalafin Hydrogel for the treatment of mild to moderate atopic dermatitis. Zabalafin Hydrogel is unique in its ability to directly treat all the problems of AD, specifically directly treating the bacterial cause of AD, directly treating AD's pruritus (itch), and directly treating the immuno-inflammatory cause of the disease.

Maryland-founded healthcare company continues to lead in medical diagnostic innovation

COLUMBIA, Md., (February 18, 2025) — TEDCO, Maryland’s economic engine for technology companies, announced a recent $500,000 dual investment in Novel Microdevices, a company aiming to provide quality point-of-care diagnostics. This investment included $250,000 from the Venture Funds and $250,000 from the Inclusion Fund, a fund under the Social Impact Funds umbrella.

“Our company has made incredible progress during the past year since TEDCO chose to invest in our vision,” said Andrea Pais, CEO of Novel Microdevices “This investment will play an important role in ensuring our product, NovelDx, makes an impact in the healthcare industry.”

Novel Microdevices, located in Baltimore, Md., is a medical device company developing a solution for clinical diagnostics. Through research and development efforts, the company founded the NovelDx device – a solution that seeks to challenge the point-of-care antigen and molecular testing market by providing lab-level PCR tests in under 15 minutes.

The Deloitte AI Institute has launched a new video series, You, Me, and Three: GenAI Questions, featuring industry leaders discussing the rapid transformation of federal health through generative AI and automation. BHI Board of Directors Member Juergen Klenk, Principal at Deloitte Consulting LLP, joined Beena Ammanath in this series to explore how organizations can cut through the AI hype and establish trust around AI. Watch the full series to gain insights from cross-industry experts on the future of AI in healthcare.

https://youtu.be/dNFsBSjBCFc

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced ultraRapid Whole Genome Sequencing, offering accelerated and comprehensive genomic insights for neonatal and pediatric patients in the NICU and PICU in as soon as 2 days.

BALTIMORE, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Elixirgen Therapeutics, Inc., a clinical-stage biotechnology company focused on treating rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to EXG-34217, a gene therapy for treatment of Telomere Biology Disorders (TBDs). EXG-34217 is currently being studied in an ongoing Phase 1/2 trial (NCT04211714) for the treatment of patients with TBDs with bone marrow failure. Enrollment is currently open for participants aged 12 and older, regardless of gender or ethnicity.

By Conor Gowder & Mark Skinner

The Feb. 7, 2025, memo from the NIH Office of the Director (NOT-OD-25-068), now on hold because of two federal judge actions, announced the implementation of a flat 15% Facilities and Administrative fee (F&A) “across all NIH grants.” While the historic average F&A, or indirect cost rate, paid for by NIH is between 27 and 28%, the memo stated, the agency has previously allowed private small businesses without a negotiated F&A rate to charge up to 40% on their SBIR/STTR awards without further justification, drastically lowering their administrative burdens. Thus, a flat 15% fee on F&A if ever implemented would likely lead to some hardship for the small businesses.

The sixth cohort will undergo the first iteration of the program’s new structure

COLUMBIA, Md., (February 13, 2025) — TEDCO, Maryland’s economic engine for technology companies, announced the sixth SBIR/STTR Proposal Lab cohort that will consist of 28 companies. Through this program, companies will learn about foundational skills in business planning, commercialization and proposal writing.

“TEDCO is committed to uplifting Maryland’s entire ecosystem; one way we do that is by providing opportunities to engage with experts and receive comprehensive training materials,” TEDCO CEO Troy LeMaile-Stovall explained. “The success of this program has prompted its growth into two parts – one focusing on foundational skills and the second focusing on opportunities to enhance quality and submission readiness of the proposals.”

TG Therapeutics to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support the development and commercialization of azer-cel, its allogeneic CD19 CAR T cell therapy program, for the treatment of autoimmune diseases

ROCKVILLE, Md., Feb. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, today announced they are entering into a strategic platform license (SPL) with TG Therapeutics, a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases.

Under the terms of the agreement, TG Therapeutics obtains non-exclusive research, clinical and commercial rights to use MaxCyte’s Flow Electroporation^® technology and ExPERT™ platform. In return, MaxCyte is entitled to receive annual licensing fees and program-related revenue.

WASHINGTON, DC / BERN, SWITZERLAND - Children’s National Hospital and Compremium AG entered into a strategic partnership to develop and commercialize cutting-edge medical technologies for the pediatric population. This partnership will bring Compremium’s non-invasive and AI-enhanced technology to the forefront of pediatric healthcare.
Diagnosing pressure-related conditions without complicated, invasive procedures has long been a challenge in the medical community. Compremium’s technology aims to transform the diagnosis of pressure physiologies, including venous pressure, intracranial pressure, and tissue pressure conditions with their non-invasive, point of care solution. Through this strategic collaboration, Children’s National will serve as the Pediatric Innovation Hub for Compremium, leading clinical studies, research projects, and commercialization efforts focused on non-invasive pressure monitoring and other breakthrough technologies.

Collaboration Aims to Develop First Intranasal Therapy for Mild Traumatic Brain Injury Aka Concussion, Establishing a Comprehensive Test-to-Treat Platform

SARASOTA, Fla. and RICHMOND, Va., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions, today announced a strategic partnership with BRAINBox Solutions, a leader in multi-modality diagnostics for traumatic brain injury (TBI). This collaboration seeks to develop the first intranasal therapy for mild traumatic brain injury (mTBI) aka concussion, creating a comprehensive trigger-to-treat platform by combining BRAINBox’s advanced multimarker/ multimodality diagnostic capabilities with Oragenics’ novel therapeutic development.

As we celebrate Women in Science Day and Women’s History Month, we are proud to spotlight the women of Volition.  From driving groundbreaking innovation to shaping strategic direction, our team do a fantastic job and we’d like to kick off the month of celebrations by featuring our female Directors on our Board.

The women on our Board of Directors are at the forefront of advancing science, fostering inclusivity, and paving the way for the future of health and medicine.

Dr. Ethel Rubin, who joined our Board in September 2024, has dedicated over 20 years to the life sciences sector, driving innovation and commercialisation strategies. Her advice to young women entering science? “Let your intellectual curiosity guide you.” She encourages future scientists to be true to themselves in choosing their career paths—whether they’re solving real-world problems or diving deep into basic biology. Ethel also highlights the importance of perseverance:

By Brian Darmody: While the Maryland economy is facing budget uncertainties, the state can help surmount these challenges by growing private growth industries, converting research into jobs, connecting the region, and attracting federal funding from those few federal budgets (defense and economic competitiveness) that are likely to grow.

Here’s how:

Winning the technology race with China will be a bipartisan effort in Congress and with the White House and state of Maryland has a role to play. The Department of Defense (DOD) R&D budget is expected to grow, including its University Affiliated Research Centers (UARCs) that ensure essential engineering and technology capability are maintained.

New Study Highlights Importance of Measuring Well-Being in Mental Health Research

WASHINGTON (February 10, 2025) – A new study published in Nature Mental Health underscores the critical role of assessing well-being in clinical research and treatment. 

Led by Fallon Goodman of the George Washington University, the study highlights how well-being, beyond the absence of mental illness, is essential for long-term health outcomes, including resilience, recovery, and overall quality of life.

Despite its importance, well-being is often overlooked in mental health research. The study identifies challenges in measuring well-being, such as inconsistencies in assessment methods, and offers recommendations to improve research approaches. By incorporating well-being metrics into clinical trials and treatment evaluations, researchers and clinicians can gain a more comprehensive understanding of mental health and enhance patient outcomes.

What does it take to establish Maryland as a powerhouse for biotech commercialization? In this episode of BioTalk with Rich Bendis, Dr. Deborah Hemingway, Founder and Managing Partner of Ecphora Capital, shares her insights on the current investment landscape in the BioHealth Capital Region. She discusses the strategic advantages that make Maryland uniquely positioned for success, the critical gaps that must be addressed, and how state and local governments can provide essential support through tax credits, grants, and economic incentives.

Dr. Hemingway also highlights Ecphora Capital’s impact, having deployed $15 million in the last two years, and reveals the firm’s strategy for future investments, including SPVs and a dedicated fund. With deep experience in medtech commercialization, strategic partnerships, and early-stage investing, she offers valuable perspectives on where the industry is headed in 2025 and how companies can thrive in an evolving biotech ecosystem.

Listen via your favorite podcast platform:
Apple: https://apple.co/40QvxJg
Spotify: https://spoti.fi/3WWEvTZ
Amazon Music: https://amzn.to/3QbxZoH
YouTube Music: https://bit.ly/40T7xVF
TuneIn: https://bit.ly/42LITcb

Tune in for a compelling conversation on innovation, investment, and the future of biotech in the BioHealth Capital Region.

GERMANTOWN, Md., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced it has filed for CE Mark registration for the Eversense^® 365 CGM system.

Eversense 365 is the world’s first and only one year CGM, which was approved by the United States (US) Food and Drug Administration in September of 2024 and launched across the country in October of the same year.